套细胞淋巴瘤患者接受长期伊布替尼联合维奈克拉治疗的免疫恢复
本研究评估套细胞淋巴瘤患者接受维奈克拉联合伊布替尼治疗4年间免疫亚群的变化。多参数流式细胞术显示治疗≥12个月后多个免疫亚群比例改变,尤以CD4+和CD8+效应及中央记忆T细胞和自然杀伤细胞为著,且T细胞受体刺激后T细胞因子产生恢复正常。基因表达分析发现12个月内多个髓系基因和炎症通路上调。4例深度缓解患者停药后除髓系基因/通路表达外所有研究参数均恢复正常免疫亚群,提示长期联合治疗不可逆影响该群体。
要点
- 长期维奈克拉联合伊布替尼治疗与套细胞淋巴瘤患者免疫恢复相关
- 治疗≥12个月后CD4+和CD8+效应及中央记忆T细胞和自然杀伤细胞比例改变
- 停药后除髓系基因/通路表达外免疫亚群均恢复正常
核心结论
- 长期联合维奈克拉和伊布替尼治疗与套细胞淋巴瘤患者免疫恢复相关,可能有利于后续免疫治疗应答。
研究设计与样本
- 评估套细胞淋巴瘤患者接受维奈克拉联合伊布替尼治疗4年间免疫亚群变化的研究,试验注册号NCT02471391。
主要发现
- 治疗≥12个月后多个免疫亚群比例改变,尤以CD4+和CD8+效应及中央记忆T细胞和自然杀伤细胞为著,T细胞受体刺激后T细胞因子产生恢复正常。
- 基因表达分析发现12个月内多个髓系基因(包括S100和cathepsin家族成员)和炎症通路上调。
- 4例深度缓解患者停药后除髓系基因/通路表达外所有研究参数均恢复正常免疫亚群。
临床怎么用
- 长期维奈克拉联合伊布替尼治疗可能通过免疫恢复使套细胞淋巴瘤患者后续免疫治疗获益。
局限性
- 长期联合治疗对髓系基因/通路表达的不可逆影响提示该群体存在持续免疫改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Combination venetoclax plus ibrutinib for the treatment of mantle cell lymphoma (MCL) has demonstrated efficacy in the relapsed or refractory setting; however, the long-term impact on patient immunology is unknown. In this study, changes in immune subsets of MCL patients treated with combination venetoclax and ibrutinib were assessed over a 4-year period. Multiparameter flow cytometry of peripheral blood mononuclear cells showed that ≥12 months of treatment resulted in alterations in the proportions of multiple immune subsets, most notably CD4+ and CD8+ effector and central memory T cells and natural killer cells, and normalization of T-cell cytokine production in response to T-cell receptor stimulation. Gene expression analysis identified upregulation of multiple myeloid genes (including S100 and cathepsin family members) and inflammatory pathways over 12 months. Four patients with deep responses stopped study drugs, resulting in restoration of normal immune subsets for all study parameters except myeloid gene/pathway expression, suggesting long-term combination venetoclax and ibrutinib irreversibly affects this population. Our findings demonstrate that long-term combination therapy is associated with immune recovery in MCL, which may allow responses to subsequent immunotherapies and suggests that this targeted therapy results in beneficial impacts on immunological recovery. This trial was registered at www.clinicaltrials.gov as #NCT02471391.
引用
- Davis JE, Handunnetti SM, Ludford-Menting M, et al. Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. Blood Adv. 2020. PMID: 33031542. doi:10.1182/bloodadvances.2020002810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。